A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation

被引:179
作者
Meissner, Winfried [2 ]
Leyendecker, Petra [1 ]
Mueller-Lissner, Stefan [4 ]
Nadstawek, Joachim [5 ]
Hopp, Michael [1 ]
Ruckes, Christian [1 ]
Wirz, Stefan [5 ]
Fleischer, Wolfgang [1 ]
Reimer, Karen [3 ]
机构
[1] Mundipharma Res GmbH & Co KG, D-65549 Limburg, Lahn, Germany
[2] Friedrich Schiller Univ, Clin Anaesthesiol & Intens Car, D-07740 Jena, Germany
[3] Univ Witten Herdecke, D-58448 Witten, Germany
[4] Pk Klin Wiessensee, D-13086 Berlin, Germany
[5] Univ Bonn, Clin Anaesthesiol & Intens Care Med, D-53131 Bonn, Germany
关键词
Oxycodone; Naloxone; Opioid-induced constipation; Bowel function; Analgesia; INDUCED BOWEL DYSFUNCTION; DIABETIC-NEUROPATHY; MANAGEMENT; PAIN; ANTAGONIST; MORPHINE; CANCER; GUT;
D O I
10.1016/j.ejpain.2008.06.012
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Opioid-induced constipation can have a major negative impact on patients' quality of life. This randomised, double-blinded study evaluated the analgesic efficacy of prolonged-release (PR) oral oxycodone when co-administered with PR oral naloxone, and its impact on opioid-induced constipation in patients with severe chronic pain. Another objective was to identify the optimal dose ratio of oxycodone and naloxone. Methods: A total of 202 patients with chronic pain (mainly non-cancer related, 2.5% of patients had cancer-related pain) under stable oral oxycodone therapy (40, 60 or 80 mg/day) were randomised to receive 10, 20, 40 mg/day naloxone or placebo. After a 4-week maintenance phase, patients received oxycodone only for 2 weeks. Pain intensity was evaluated using a numerical analogue scale and bowel function was assessed using the bowel function index. Results: No loss of analgesic efficacy with naloxone was observed. Mean pain intensity scores on randomisation were comparable for placebo, 10 mg. 20 mg and 40 mg naloxone dose, and remained unchanged during treatment. Bowel function improved with increasing naloxone dose. Naloxone 20 mg and 40 mg significantly improved bowel function at the end of the maintenance phase compared with placebo (p < 0.05). Overall, the combination was well tolerated, with no unexpected adverse events. There was a trend towards an increased incidence of diarrhoea with higher doses of naloxone. The 2:1 oxycodone/naloxone ratio was identified as the most suitable for further development. Conclusion: Co-administration of PR oral naloxone and PR oral oxycodone is associated with a significant improvement in bowel function compared with PR oral oxycodone alone, with no reduction in the analgesic efficacy of oxycodone. (C) 2008 European Federation of Chapters of the international Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:56 / 64
页数:9
相关论文
共 25 条
[1]   Strategies to manage the adverse effects of oral morphine: An evidence-based report [J].
Cherny, N ;
Ripamonti, C ;
Pereira, J ;
Davis, C ;
Fallon, M ;
McQuay, H ;
Mercadante, S ;
Pasternak, G ;
Ventafridda, V .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2542-2554
[2]  
Coluzzi F, 2005, Minerva Anestesiol, V71, P451
[3]   TREATMENT OF OPIOID-INDUCED CONSTIPATION WITH ORAL NALOXONE - A PILOT-STUDY [J].
CULPEPPERMORGAN, JA ;
INTURRISI, CE ;
PORTENOY, RK ;
FOLEY, K ;
HOUDE, RW ;
MARSH, F ;
KREEK, MJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) :90-95
[4]   Opioids and the gut: pharmacology and current clinical experience [J].
De Schepper, HU ;
Cremonini, F ;
Park, MI ;
Camilleri, M .
NEUROGASTROENTEROLOGY AND MOTILITY, 2004, 16 (04) :383-394
[5]   Insights into opioid action in the intestinal tract [J].
DeLuca, A ;
Coupar, IM .
PHARMACOLOGY & THERAPEUTICS, 1996, 69 (02) :103-115
[6]  
DERBY P, 1998, TOPICS PALLIATIVE CA, P95
[7]   Controlled-release oxycodone for pain in diabetic neuropathy - A randomized controlled trial [J].
Gimbel, JS ;
Richards, P ;
Portenoy, RK .
NEUROLOGY, 2003, 60 (06) :927-934
[8]   Central & peripheral nervous systems - Treatment of opioid-induced gut dysfunction [J].
Holzer, Peter .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (02) :181-194
[9]   Oxycodone [J].
Kalso, E .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2005, 29 (05) :S47-S56
[10]   NALOXONE, A SPECIFIC OPIOID ANTAGONIST, REVERSES CHRONIC IDIOPATHIC CONSTIPATION [J].
KREEK, MJ ;
HAHN, EF ;
SCHAEFER, RA ;
FISHMAN, J .
LANCET, 1983, 1 (8319) :261-262